Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.76 |
| ▸ | MAPT | P10636 | 2/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.56 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.54 |
| ▸ | FLT1 | P17948 | 2/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | HTR1E | P28566 | 1/20 | 0.52 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146791 | 0.92 | NPSR1 (0.78) | NPSR1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL1900773 | 0.91 | NPSR1 (0.90) | NPSR1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL147011 | 0.88 | NPSR1 (0.65) | NPSR1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL7744394 | 0.87 | NPSR1 (0.64) | NPSR1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL7744959 | 0.86 | NPSR1 (1.00) | NPSR1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL147214 | 0.81 | MAPT (0.67) | NPSR1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL147989 | 0.81 | NPSR1 (0.80) | NPSR1MAPTMAPK1PTGDR2HTR1E | |
| SCHEMBL1897475 | 0.75 | NPSR1 (0.48) | NPSR1MAPTMAPK1P2RY14PTGDR2 | |
| SCHEMBL1897882 | 0.75 | RAB9A (1.00) | NPSR1MAPTKMT2ANPC1RAB9A | |
| SCHEMBL1899459 | 0.75 | NPSR1 (1.00) | NPSR1MAPTKMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | VERVA PHARMACEUTICALS PTY LTD (AU) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059047-A1 | DIFFERENTIATION MODULATING AGENTS AND USES THEREFOR | FGF1, FABP4, FGF2 | NPSR1 3871/4885MAPT 4367/4885KMT2A 3024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.